622 d for all pentamidine recipients), including 6% who died of pentamidine toxicities [one proven postmortem to have a (non-functional) homozygous CYP2C19*2 mutation]. Charges for care attributable to pentamidine
toxicity exceeded what preemptive genotyping would have cost by 73-fold. These findings encourage routine use of preemptive CYP2C19 genotyping in alloSCT patients considered for pentamidine.”
“The shock compression response of several THV-alumina particle composites (where THV is a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinyldiene fluoride) was investigated based on experiments performed in the pressure range of 2-6 GPa. The composites, composed of 25% by volume of either 1, 10, or 100 mu m Al(2)O(3), had varying degrees of porosity. The high level of porosity,
particularly in the 1 mu m Al(2)O(3) composite, obscured determination of any particle size effects. In general, the composites displayed a stiffer GSK461364 in vitro shock response than expected, based on the known response of the constituent materials, with the 10 mu m Al(2)O(3) composite being slightly stiffer than the 100 mu m composite. CCI-779 It is argued that a possible way to describe the stiffer shock compression response is by assigning a higher value for the “”effective”" Gruneisen parameter gamma to the composites. The higher value is consistent with arguments made in the literature that gamma for polymers is much GDC-0449 higher (by as much as
an order of magnitude) than the often reported values (generally similar to 1 or less for polymers). The particle size effect can, however, possibly explain the difference in the stiffness between 10 and 100 mu m Al(2)O(3) composites, which is consistent with results reported in the literature. (C) 2011 American Institute of Physics. [doi:10.1063/1.3525761]“
“Background:
There is lack of knowledge to what degree clinical/morphological presentation and course of IgA nephropathy (IgAN) prior to end-stage renal disease are risk factors for graft loss after kidney transplantation.
Material and Methods:
Patients with IgAN between 1988 and 2006 (registered in the Norwegian Kidney Biopsy Registry) who later received a kidney transplant (registered in the Norwegian Renal Registry) were included. The cohort was followed up regarding death-censored graft loss throughout 2008. Graft survival with a rapid progressive (RP) vs. a slow progressive (SP) course of pre-Tx IgAN (annual GFR > or < 30 mL/min/1.73 m2) was studied.
Results:
Among 106 included patients, there were 14 graft losses giving a graft loss rate of 1.9/100 patient years. Follow-up until the first kidney transplant was 6.9 +/- 4.4 (range 0.1-19) yr. Patients with pre-Tx RP had a higher graft loss rate compared with SP patients (6.3 vs.1.3/100 patient years, p < 0.001). Graft loss rate with living-related donor (LRD) was similar to unrelated donor (UD) grafts.